Study of new injection for moderate-to-severe plaque psoriasis
This study tests a new injectable medicine for people with moderate-to-severe plaque psoriasis. It aims to see if it is safe and effective at reducing symptoms like redness and scaling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have had plaque psoriasis for at least 6 months
- Psoriasis covers at least 10% of your body surface area
- Have moderate-to-severe psoriasis as rated by a doctor
- Be a candidate for phototherapy or systemic treatment
- Be willing to use effective contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-20137 for people with moderate to severe plaque psoriasis. It might help reduce skin symptoms like redness, scaling, and itching.
This trial tests a new tablet called SYHX1901 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and quality of life over several months.
This trial tests an oral tablet (CMS-D001) for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing psoriasis severity.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
This study tests a new oral pill (HSK47388) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing the severity and area of psoriasis over 12 weeks.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.